#None #NCCN #melanoma #Merlin CP-GEP

Significant Recognition for Merlin CP-GEP

In a notable advancement for melanoma diagnosis, SkylineDx has announced that the National Comprehensive Cancer Network® (NCCN®) has formally recognized the Merlin CP-GEP test in its updated Clinical Practice Guidelines for oncology concerning cutaneous melanoma. A pivotal aspect of this inclusion is that it marks Merlin CP-GEP as the first and only molecular test acknowledged by the NCCN for specific early-stage melanoma patients.

Importance of the NCCN Guidelines

The NCCN guidelines play a crucial role in shaping clinical practices, providing recommendations that healthcare professionals rely on for managing cancer treatment effectively. In the latest version (1.2026), the guidelines specifically endorse Merlin CP-GEP for T1 and T2 melanoma patients, highlighting the necessity of accurately evaluating the metastatic risks in these groups. This endorsement is particularly pivotal as it illustrates the NCCN’s recognition of the importance of integrating molecular diagnostics in clinical decision-making.

According to data from the MERLIN_001 trial, patients classified as high risk by the Merlin CP-GEP test have been shown to possess nearly a threefold higher likelihood of sentinel lymph node (SLN) involvement. Such insights gained from molecular testing stand to substantially enhance personalized treatment plans, guiding physicians in making informed decisions.

Differentiating Merlin CP-GEP from Other Tests

The NCCN panel has also differentiated Merlin CP-GEP from other competing gene expression profile tests on the market, such as Castle Biosciences’ DecisionDx® Melanoma. Unlike these alternatives, the NCCN specifically advises against using other GEP assays for SLNB risk assessment outside a clinical trial, thereby underscoring Merlin CP-GEP’s unique standing as a clinically validated option.

“Receiving this update is a significant milestone in our mission to facilitate personalized cancer care,” stated Dharminder Chahal, CEO of SkylineDx. “Patients with early melanoma should have access to risk assessment tools that underscore rigorous validation and evidence. The adoption of Merlin CP-GEP by the NCCN marks a shift towards a more nuanced and precise understanding of each patient's metastatic risk.”

The Mechanism Behind Merlin CP-GEP

Merlin CP-GEP is a non-invasive molecular testing option that fuses clinicopathologic variables with gene expression profiling to produce a detailed assessment of metastatic risk for early-stage melanoma patients. This dual approach focuses on biological insights to supplement traditional staging, thus empowering both healthcare professionals and patients to engage in effective discussions regarding treatment strategies.

The Merlin CP-GEP test, available in both the U.S. and Europe, continues to build a robust database of long-term prospective outcome data through ongoing studies like the MERLIN_001. This commitment ensures that precision medicine remains at the forefront of patient care in the melanoma treatment landscape.

For more in-depth information about the Merlin CP-GEP test and its implications, visitors can check out Merlin melanoma test.

About SkylineDx

SkylineDx focuses on the development of molecular diagnostics to enhance clinical outcomes in oncology and infectious diseases. By linking academic research on gene expressions with commercially viable diagnostic tools, the firm aims to aid healthcare providers in tailoring treatments based on patient-specific data. With a stronghold in both the Netherlands and California, SkylineDx exemplifies a commitment to advancing cancer care through innovation and scientific rigor.